Bimekizumab Maintains Improvements in Efficacy Endpoints and has a Consistent Safety Profile Through 52 Weeks in Patients with Non-Radiographic Axial Spondyloarthritis and Ankylosing Spondylitis: Results from Two Parallel Phase 3 Studies
Xenofon Baraliakos, Atul Deodhar, Désirée van der Heijde, Marina Magrey, Walter P.Maksymowych, Tetsuya Tomita, Huji Xu, Marga Oortgiesen, Ute Massow, Carmen Fleurinck, Alicia M. Ellis, Tom Vaux, Julie Shepherd‐Smith, Alexander Marten, Lianne S. Gensler
Abstract or description:
This poster reports key efficacy outcomes such as ASAS40 response at Week 16 and Week 52 for the overall population and in TNFi-naïve and TNFi-experienced patients. The poster also discusses patients treated with BKZ achieving low disease activity (LDA) based on the ASDAS scores, objective signs of inflammation. An overview of safety and patient disposition to Week 52 will also be given.